BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 122944
Published online Nov 24, 2026. doi: 10.5306/wjco.122944
Table 2 Long-term outcomes after excluding postoperative early deaths, n (%)/mean ± SD

Group I (n = 1029)
Group II (n = 157)
Group III (n = 154)
Group IV (n = 210)
P value
Period of follow-up (months)57.3 ± 21.953.9 ± 25.446.0 ± 24.341.7 ± 22.7< 0.001
Recurrence during the follow-up541 (52.6)97 (61.8)106 (68.8)148 (70.5)< 0.001
Intrahepatic recurrence499 (48.5)89 (56.7)90 (58.4)130 (61.9)0.001
Extrahepatic recurrence18 (1.7)3 (1.9)4 (2.6)5 (2.4)0.858
Intra- and extrahepatic recurrence24 (2.3)5 (3.2)12 (7.8)13 (6.5)0.001
BCLC stage of initial recurrence541 (52.6)97 (61.8)106 (68.8)148 (70.5)< 0.001
BCLC A stage345 (33.5)55 (35.0)53 (34.4)61 (29.0)0.568
BCLC B stage142 (13.8)31 (19.7)31 (20.1)61 (29.0)< 0.001
BCLC C stage54 (5.2)11 (7.0)22 (14.3)26 (12.4)< 0.001
Mortality during the follow-up380 (36.9)74 (47.1)85 (55.2)136 (64.8)< 0.001
Cancer-specific mortality318 (30.9)65 (41.4)73 (47.4)117 (55.7)< 0.001
Non-cancer-specific mortality62 (6.0)9 (5.7)12 (7.8)19 (9.0)0.370
Overall survival 107.7 (-)76.4 (57.8-95.0)51.0 (33.6-68.5)43.0 (33.8-52.2)< 0.001
1-year OS rate (%)96.191.791.688.1
3-year OS rate (%)80.373.263.071.0
5-year OS rate (%)68.259.447.836.7
Recurrence free survival 48.8 (41.7-55.9)38.4 (21.9-55.0)19.2 (12.2-26.2)13.6 (8.9-18.3)< 0.001
1-year RFS rate (%)75.972.059.753.3
3-year RFS rate (%)56.050.335.732.9
5-year RFS rate (%)45.639.129.724.2


Write to the Help Desk